145 related articles for article (PubMed ID: 9804691)
21. Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction.
Shim JY; Welsh WJ; Howlett AC
Biopolymers; 2003; 71(2):169-89. PubMed ID: 12767117
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233.
Dhawan J; Deng H; Gatley SJ; Makriyannis A; Akinfeleye T; Bruneus M; Dimaio AA; Gifford AN
Synapse; 2006 Aug; 60(2):93-101. PubMed ID: 16715483
[TBL] [Abstract][Full Text] [Related]
23. Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids.
Wiley JL; Marusich JA; Huffman JW
Life Sci; 2014 Feb; 97(1):55-63. PubMed ID: 24071522
[TBL] [Abstract][Full Text] [Related]
24. Cannabinoid penetration into mouse brain as determined by ex vivo binding.
Petitet F; Jeantaud B; Bertrand P; Imperato A
Eur J Pharmacol; 1999 Jun; 374(3):417-21. PubMed ID: 10422786
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors.
Nakazi M; Bauer U; Nickel T; Kathmann M; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2000 Jan; 361(1):19-24. PubMed ID: 10651142
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, ligand binding, and QSAR (CoMFA and classical) study of 3 beta-(3'-substituted phenyl)-, 3 beta-(4'-substituted phenyl)-, and 3 beta-(3',4'-disubstituted phenyl)tropane-2 beta-carboxylic acid methyl esters.
Carroll FI; Mascarella SW; Kuzemko MA; Gao Y; Abraham P; Lewin AH; Boja JW; Kuhar MJ
J Med Chem; 1994 Sep; 37(18):2865-73. PubMed ID: 8071935
[TBL] [Abstract][Full Text] [Related]
27. 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor.
Huffman JW; Mabon R; Wu MJ; Lu J; Hart R; Hurst DP; Reggio PH; Wiley JL; Martin BR
Bioorg Med Chem; 2003 Feb; 11(4):539-49. PubMed ID: 12538019
[TBL] [Abstract][Full Text] [Related]
28. Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1.
Chin CN; Lucas-Lenard J; Abadji V; Kendall DA
J Neurochem; 1998 Jan; 70(1):366-73. PubMed ID: 9422383
[TBL] [Abstract][Full Text] [Related]
29. Characterization of aminoalkylindole binding: selective displacement by cannabinoids.
Haycock DA; Kuster JE; Stevenson JI; Ward SJ; D'Ambra T
NIDA Res Monogr; 1990; 105():304-5. PubMed ID: 1876020
[No Abstract] [Full Text] [Related]
30. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain.
Kathmann M; Bauer U; Schlicker E; Göthert M
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):466-70. PubMed ID: 10431757
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, binding and docking-based 3D-QSAR studies of 2-pyridylbenzimidazoles--a new family of high affinity CB1 cannabinoid ligands.
Mella-Raipán JA; Lagos CF; Recabarren-Gajardo G; Espinosa-Bustos C; Romero-Parra J; Pessoa-Mahana H; Iturriaga-Vásquez P; Pessoa-Mahana CD
Molecules; 2013 Apr; 18(4):3972-4001. PubMed ID: 23558540
[TBL] [Abstract][Full Text] [Related]
32. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds.
Sugiura T; Kodaka T; Nakane S; Miyashita T; Kondo S; Suhara Y; Takayama H; Waku K; Seki C; Baba N; Ishima Y
J Biol Chem; 1999 Jan; 274(5):2794-801. PubMed ID: 9915812
[TBL] [Abstract][Full Text] [Related]
33. The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor.
Chin CN; Murphy JW; Huffman JW; Kendall DA
J Pharmacol Exp Ther; 1999 Nov; 291(2):837-44. PubMed ID: 10525107
[TBL] [Abstract][Full Text] [Related]
34. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2.
Fattore L; Viganò D; Fadda P; Rubino T; Fratta W; Parolaro D
Eur J Neurosci; 2007 Apr; 25(7):2191-200. PubMed ID: 17419755
[TBL] [Abstract][Full Text] [Related]
35. Cannabimimetic indoles, pyrroles and indenes.
Huffman JW
Curr Med Chem; 1999 Aug; 6(8):705-20. PubMed ID: 10469887
[TBL] [Abstract][Full Text] [Related]
36. Three-dimensional quantitative structure-activity relationships of 5-HT receptor binding data for tetrahydropyridinylindole derivatives: a comparison of the Hansch and CoMFA methods.
Agarwal A; Pearson PP; Taylor EW; Li HB; Dahlgren T; Herslöf M; Yang Y; Lambert G; Nelson DL; Regan JW
J Med Chem; 1993 Dec; 36(25):4006-14. PubMed ID: 8258822
[TBL] [Abstract][Full Text] [Related]
37. Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist.
Hirst RA; Almond SL; Lambert DG
Neurosci Lett; 1996 Dec; 220(2):101-4. PubMed ID: 8981483
[TBL] [Abstract][Full Text] [Related]
38. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
Lin S; Khanolkar AD; Fan P; Goutopoulos A; Qin C; Papahadjis D; Makriyannis A
J Med Chem; 1998 Dec; 41(27):5353-61. PubMed ID: 9876105
[TBL] [Abstract][Full Text] [Related]
39. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.
Castelli MP; Paola Piras A; D'Agostino A; Pibiri F; Perra S; Gessa GL; Maccarrone M; Pistis M
Eur J Pharmacol; 2007 Nov; 573(1-3):11-9. PubMed ID: 17644084
[TBL] [Abstract][Full Text] [Related]
40. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.
Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ
J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
